Year: 1994
Type: letter
Abstract: To the Editor: The results of two double-blind, randomized, placebo-controlled trials published in the Journal (Sept. 16 issue)1 have shown that prophylactic treatment with rifabutin (300 mg per day) significantly reduces the incidence of Mycobacterium avium complex bacteremia. A Special Report in the same issue2 further recommends rifabutin prophylaxis in adults and adolescents with human immunodeficiency virus infection and CD4+ counts of 100 cells or less per cubic millimeter and suggests that effective primary prophylaxis could improve the patients' quality of life and survival. Fluconazole, a potent inhibitor of cytochrome P-450, significantly (P<0.01) increases both the maximal concentration and the . . .
Source: New England Journal of Medicine
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2339838480
